What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
Yelena Janjigian, MD
PeerClaudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Samuel J. Klempner, MD
PeerWhat Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
Samuel J. Klempner, MD
PeerYelena Janjigian, MD
PeerWhat Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
Yelena Janjigian, MD
PeerYelena Janjigian, MD
PeerRoy F. Chemaly, MD, MPH
PeerKathleen Moore, MD, MS
PeerShubham Pant, MD, MBBS
PeerKathleen Moore, MD, MS
PeerKathleen Moore, MD, MS
PeerKathleen Moore, MD, MS
PeerSusana Banerjee, MBBS, MA, FRCP, PhD
Peer